Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines

European Journal of Medical Research

Volumn 11, Issue 9, 2006, Pages 377-380

  von Hentig, Nils ^a   Koenigs, C ^a   Elanjikal, S ^a   Linde, R ^a   Dunsch, D ^a   Kreuz, W ^a   Funk, M B ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Efavirenz; HIV 1

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRACTICE GUIDELINE;

ANTI-HIV AGENTS; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERNATIONAL AGENCIES; MALE; OXAZINES; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC;

EID: 33750084990     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. http://AIDSinfo.nih.gov. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2005.
2. Sharland M, Blanche S, Castelli G, et al. on behalf of the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy 2004. HIV Med 2004, 5:61-86.
3. Staszewski S, Moralez-Ramirez J, Tashima KT, et al. Study 006- Team. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999, 341: 1865-1873.
4. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363: 1253-1263.
5. Marzolini C, Telenti A, Decosterda LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001,15:71-75.
6. Brundage RC, Yong FH, Fenton T, et al. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother. 2004, 48: 979-984.
7. BristolMyersSquibb. Sustiva product information. Apr 2005. T4-B0001-04-05/Revised. princeton, NJ08543, USA. http://www.bms.com/ products/data/index.html
8. Starr SE, Fletcher CV, Spector SA, et al.; PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group. Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002, 21:659-663.
9. Fraaij PL, Neubert J, Bergshoeff AS, et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir Ther 2004, 9:297-299.
10. Bergshoeff AS, Fraaij PL, Ndagijimana J, et al.. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1 -infected children. J Acquit Immune Defic Syndr. 2005; 39(1): 63-8
11. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis 2005,41:100-107.
12. Teglas JP, Quartier P, Treluyer JM, et al. Tolerance of efavirenz in children. AIDS 2001, 15: 241-243.
13. Funk MB, Notheis G, Schuster T, et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Eur J Med Res 2005,10:503-508.
14. Niehues T, Wintergerst U, Funk MB, et al. Empfehlung zur antireroviralen Therapie bei HIV-infizierten Kinder - Konsensusstatement der Pädiatrische Arbeitsgruppe AIDS (PAAD) (german). Monatsschr Kinderheilk 2001,149:1372-1382.
15. Marzolini C, Telenti A, Buclin T, et al. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Sci Appl. 2000, 740: 43-58.
16. WinNonLin®. Version distributed by Pharsight Corporation, USA. 2004.
17. SPSS für Windows®. Version 11.5 (deutsch) 2004.
18. GraphPadPrism®. Version (deutsch). 2004,4.01.
19. Starr SE, Fletscher CV, Spector SA., et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med. 1999 Dec 16; 341(25):1874-81.
20. Nettles R, Kieffer T, Parsons T, et al. Frequent sampling in virologically suppressed patients taking HIV protease inhibitors of non-nucleoside reverse transcriptase inhibitors defines intra-individual pharmacokinetic variability. In: 12th Conference on Retroviruses and opportunistic Infections, Boston, USA 2005, Abstract 642.